AUS
NZ
UK
CA
USA
IND
Highlights
- Expansion of Remplir™ adoption in the US market
- Strategic VAC approvals progressing across key hospitals
- Strengthened logistics and specialist team support in place
Orthocell Ltd (ASX:OCC) is advancing its presence in the US nerve repair market with the continued rollout of its flagship product, Remplir™. The product, already utilised in procedures across Australia and Singapore, is now making headway in the United States with successful early surgeries helping build clinical confidence. These initial cases have been strategically important in previous markets, contributing to stronger adoption and greater market reach.
In the highly specialised nerve repair segment, establishing early familiarity among surgeons is a key step toward achieving broader usage. Orthocell’s strategy includes working closely with its network of distributors to identify hospitals and secure necessary approvals, laying the groundwork for sustained revenue growth.
Progress with Value Assessment Committee Approvals
The company has submitted multiple applications to hospital Value Assessment Committees (VACs), the bodies responsible for evaluating new medical technologies before integration into surgical practice. Several approvals have already been granted, with more under review. Target hospitals have been selected in partnership with experienced distributors operating across a wide US network, ensuring access to the right facilities and specialist surgeons.
Logistics, Supply, and Team Expansion
Orthocell has completed the shipment of thousands of Remplir™ units to its US logistics partner, ensuring a consistent supply chain for surgical procedures. All products are manufactured at the company’s Western Australian facility, maintaining strict quality standards.
To reinforce its commercial push, Orthocell has expanded its US-based team, bringing in expertise directly relevant to the nerve repair market. This investment in people and infrastructure supports the company’s goal of increasing market penetration and adoption rates.
For investors monitoring ASX 100 stocks, the company’s progress in a specialised yet growing medical field underscores the broader trend of Australian healthcare innovation gaining traction in global markets.
Frequently Asked Questions
- What is Remplir™ and how is it used?
Remplir™ is a medical device designed for nerve repair procedures, assisting surgeons in restoring nerve function after injury. - Why are VAC approvals important for Orthocell?
VAC approvals are a prerequisite for introducing new medical products into hospital systems, ensuring they meet safety, clinical, and cost-effectiveness criteria. - How does the US rollout compare to other markets?
Similar to the approach taken in Australia and Singapore, Orthocell is focusing on early adoption through targeted hospitals and surgeon engagement to encourage wider market uptake.
